RxDoctor Payments Data

Jodene Burkhart

Nurse Practitioner · Gering, NENPI 1780607556

Payments from drug & device makers

$936in general payments, 2019–2025

Across 53 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$265
  • AstraZeneca$252
  • Viatris Specialty LLC$167
  • Otsuka America Pharmaceutical, Inc.$85
  • AbbVie$75
  • Verona Pharma, Inc.$52
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$936 in reported general payments places this provider in the 70th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$131,571
Medicare patients
674
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$50,544
FarxigaDapagliflozin Propanediol49$39,493
TrulicityDulaglutide33$37,891
OzempicSemaglutide33$29,262
Invega SustennaPaliperidone Palmitate13$29,062
JardianceEmpagliflozin34$27,720
OxycontinOxycodone Hcl21$21,139
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$19,113
LinzessLinaclotide33$18,740
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$15,736
XareltoRivaroxaban26$15,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,885
InvokanaCanagliflozin20$11,259
Bydureon BciseExenatide Microspheres11$10,458
TradjentaLinagliptin13$10,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$252$39,49349 claims
AbbVieLinzess, Synthroid$75$20,68867 claims
Sanofi-aventis U.S. LLCLantus$12$3,16924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Gering

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →